Physician profile
Kristin D Scott-Tillery
NPI 1730305095
$205,738.44
in general payments reported to CMS, 2019-2025
11 companies · $12K in 2025
The $12K reported for 2025 was more than what 79% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $10K · 2021: $17K · 2022: $42K · 2023: $67K · 2024: $43K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $101K · Travel and Lodging: $19K · Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,310.00 |
| Travel and Lodging | $19,322.35 |
| Food and Beverage | $1,996.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $204,107.72 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $401.95 | 2023-2024 | Optimizer, Optimizer |
| Actelion Pharmaceuticals US, INC. | $378.88 | 2023 | Opsumit, Uptravi |
| Boston Scientific Corporation | $266.05 | 2019-2023 | Watchman Flx |
| Abbott Laboratories | $204.27 | 2021-2023 | Cardiomems |
| Astrazeneca Pharmaceuticals Lp | $133.02 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $107.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $69.44 | 2023 | Verquvo |
| Abiomed | $56.00 | 2021 | |
| Preventice Services, LLC | $13.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Scott-Tillery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.